TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of an Electronic Alert Into the Primary Care Medical Health Record to Increase Participation in a Population Colorectal Cancer Screening Program.
Brief Summary: The implementation of screening programs for colorectal cancer by screening for fecal occult blood has proven effective in reducing the incidence and mortality from this type of neoplasms. However, to ensure the efficiency of the programs require population participation rates of at least 50%. Experiences in our country show that the population participation is far from this recommended minimum number.

Interventions to promote preventive activities in primary care are well received by the population; in the case of colorectal cancer, direct recommendation of primary care professionals to carry out the screening is one of the factors with greatest impact on increasing population participation in such programs. Care overload, circuit design for screening without the direct intervention of primary care professionals and the multiplicity of tasks that they must face, are elements that influence the low recommendation for screening in the target population who consults for any other reason.

The introduction of specific reminders in electronic medical record (in widespread use in primary care), as a tool to facilitate and encourage direct referral by physicians and nurse practitioners to perform colorectal cancer screening will mean an increase of at least 10% in participation of the target population, increasing the efficiency of screening programs. The introduction of this new software tool will have good acceptance and increase compliance with recommendations from health professionals.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Cell Phone Intervention | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Cell Phone Intervention; Assigned to Arm(s): 1
B: Arm Label: electronic reminder; Type: EXPERIMENTAL; Interventions: Behavioral: electronic reminder | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: electronic reminder; Assigned to Arm(s): electronic reminder
C: Arm Label: Intervention group; Type: N/A; Interventions: Other: e-Chasqui | Arm Label: Simultaneous/historical control group; Type: N/A; Interventions: N/A | Intervention Type: OTHER; Name: e-Chasqui; Assigned to Arm(s): Intervention group
D: Arm Label: A - coded unit ID; Type: EXPERIMENTAL; Interventions: Other: clinical decision support | Arm Label: B - coded unit ID; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: clinical decision support; Assigned to Arm(s): A - coded unit ID

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Wearable Pulsed Electromagnetic Fields Device in Knee Osteoarthritis Patients: a Double Blinded, Randomized Clinical Trial
Brief Summary: The aim of the study is to evaluate the efficacy of a wearable device using pulse electromagnetic fields on pain intensity reduction, measured by visual analogue score (VAS) and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), in patients affected by osteoarthritis Secondary aim is the evaluate the effect on knee effusion reduction, when present and to evaluate pain intensity changes corrected by pain threshold measured by pressure algometry.


Options:
A: Arm Label: active; Type: ACTIVE_COMPARATOR; Interventions: Device: Wearable pulsed electromagnetic fields | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Device: Wearable pulsed electromagnetic fields | Intervention Type: DEVICE; Name: Wearable pulsed electromagnetic fields; Assigned to Arm(s): active, placebo
B: Arm Label: Treatment arm 1; Type: ACTIVE_COMPARATOR; Interventions: Other: magnetotherapy | Arm Label: Treatment arm 2; Type: ACTIVE_COMPARATOR; Interventions: Device: laser auriculotherapy | Arm Label: Treatment arm 3; Type: EXPERIMENTAL; Interventions: Other: magnetotherapy, Device: laser auriculotherapy | Arm Label: Placebo arm; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: OTHER; Name: magnetotherapy; Assigned to Arm(s): Treatment arm 1, Treatment arm 3 | Intervention Type: DEVICE; Name: laser auriculotherapy; Assigned to Arm(s): Treatment arm 2, Treatment arm 3 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo arm
C: Arm Label: High dose PSW groups; Type: EXPERIMENTAL; Interventions: Device: Pulsed short wave | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Device: Pulsed short wave | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Pulsed short wave; Assigned to Arm(s): High dose PSW groups, Placebo
D: Arm Label: exercise; Type: ACTIVE_COMPARATOR; Interventions: Other: Exercise | Arm Label: exercise + manual therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Exercise, Other: manual therapy | Arm Label: exercise + booster; Type: EXPERIMENTAL; Interventions: Other: Exercise | Arm Label: exercise + manual therapy + booster; Type: EXPERIMENTAL; Interventions: Other: Exercise, Other: manual therapy | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): exercise, exercise + booster, exercise + manual therapy, exercise + manual therapy + booster | Intervention Type: OTHER; Name: manual therapy; Assigned to Arm(s): exercise + manual therapy, exercise + manual therapy + booster

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Physiologic Comparison Between Noninvasive Neurally Adjusted Ventilatory Assist (NAVA) and Pressure Support (PS) in Preterm Infants
Brief Summary: Neurally adjusted ventilatory assist (NAVA) has been shown to improve patient- ventilator interaction and reduce asynchronies. This is a short-term physiologic comparison between PSV (pressure support ventilation) and NAVA in delivering noninvasive ventilation through a nasal cannula, in premature infants postextubation. Patients will undergo a 30-min crossover trial of noninvasive PSV and NAVA, 15 minutes each. Diaphragm electrical activity (EAdi)and airway pressure (Paw) are recorded to derive neural and mechanical respiratory rate and timing, inspiratory trigger delays time of synchrony between diaphragm contraction and ventilator assistance, and the asynchrony index (AI).


Options:
A: Arm Label: NIPPV; Type: ACTIVE_COMPARATOR; Interventions: Device: NIPPV | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Device: NIPPV | Intervention Type: DEVICE; Name: NIPPV; Assigned to Arm(s): Control, NIPPV | Intervention Type: DEVICE; Name: NIPPV; Assigned to Arm(s): Control, NIPPV | Intervention Type: DEVICE; Name: NIPPV; Assigned to Arm(s): Control, NIPPV
B: Arm Label: CPAP ventilation mode; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CPAP ventilation mode | Arm Label: NIPPV ventilation mode; Type: EXPERIMENTAL; Interventions: Procedure: NIPPV ventilation mode | Intervention Type: PROCEDURE; Name: CPAP ventilation mode; Assigned to Arm(s): CPAP ventilation mode | Intervention Type: PROCEDURE; Name: NIPPV ventilation mode; Assigned to Arm(s): NIPPV ventilation mode
C: Arm Label: NAVA-PS; Type: EXPERIMENTAL; Interventions: Device: noninvasive respiratory support with NAVA mode and PSV | Arm Label: PS-NAVA; Type: EXPERIMENTAL; Interventions: Device: noninvasive respiratory support with NAVA mode and PSV | Intervention Type: DEVICE; Name: noninvasive respiratory support with NAVA mode and PSV; Assigned to Arm(s): NAVA-PS, PS-NAVA
D: Intervention Type: DRUG; Name: Caffeine citrate injection; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Physiologic Comparison Between Noninvasive Neurally Adjusted Ventilatory Assist (NAVA) and Pressure Support (PS) in Preterm Infants
Brief Summary: Neurally adjusted ventilatory assist (NAVA) has been shown to improve patient- ventilator interaction and reduce asynchronies. This is a short-term physiologic comparison between PSV (pressure support ventilation) and NAVA in delivering noninvasive ventilation through a nasal cannula, in premature infants postextubation. Patients will undergo a 30-min crossover trial of noninvasive PSV and NAVA, 15 minutes each. Diaphragm electrical activity (EAdi)and airway pressure (Paw) are recorded to derive neural and mechanical respiratory rate and timing, inspiratory trigger delays time of synchrony between diaphragm contraction and ventilator assistance, and the asynchrony index (AI).


Options:
A: Arm Label: NAVA-PS; Type: EXPERIMENTAL; Interventions: Device: noninvasive respiratory support with NAVA mode and PSV | Arm Label: PS-NAVA; Type: EXPERIMENTAL; Interventions: Device: noninvasive respiratory support with NAVA mode and PSV | Intervention Type: DEVICE; Name: noninvasive respiratory support with NAVA mode and PSV; Assigned to Arm(s): NAVA-PS, PS-NAVA
B: Arm Label: Nasal Continuous Positive Airway Pressure (CPAP); Type: ACTIVE_COMPARATOR; Interventions: Device: Nasal CPAP (SLE) | Arm Label: Nasal Intermittent Mandatory Ventilation (IMV); Type: ACTIVE_COMPARATOR; Interventions: Device: Nasal IMV (SLE) | Intervention Type: DEVICE; Name: Nasal CPAP (SLE); Assigned to Arm(s): Nasal Continuous Positive Airway Pressure (CPAP) | Intervention Type: DEVICE; Name: Nasal IMV (SLE); Assigned to Arm(s): Nasal Intermittent Mandatory Ventilation (IMV)
C: Arm Label: NCPAP; Type: ACTIVE_COMPARATOR; Interventions: Device: nasal intermittent positive pressure ventilation | Arm Label: NIPPV; Type: EXPERIMENTAL; Interventions: Device: nasal intermittent positive pressure ventilation | Intervention Type: DEVICE; Name: nasal intermittent positive pressure ventilation; Assigned to Arm(s): NCPAP, NIPPV
D: Arm Label: NIPPV; Type: ACTIVE_COMPARATOR; Interventions: Device: NIPPV | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Device: NIPPV | Intervention Type: DEVICE; Name: NIPPV; Assigned to Arm(s): Control, NIPPV | Intervention Type: DEVICE; Name: NIPPV; Assigned to Arm(s): Control, NIPPV | Intervention Type: DEVICE; Name: NIPPV; Assigned to Arm(s): Control, NIPPV

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Physiologic Comparison Between Noninvasive Neurally Adjusted Ventilatory Assist (NAVA) and Pressure Support (PS) in Preterm Infants
Brief Summary: Neurally adjusted ventilatory assist (NAVA) has been shown to improve patient- ventilator interaction and reduce asynchronies. This is a short-term physiologic comparison between PSV (pressure support ventilation) and NAVA in delivering noninvasive ventilation through a nasal cannula, in premature infants postextubation. Patients will undergo a 30-min crossover trial of noninvasive PSV and NAVA, 15 minutes each. Diaphragm electrical activity (EAdi)and airway pressure (Paw) are recorded to derive neural and mechanical respiratory rate and timing, inspiratory trigger delays time of synchrony between diaphragm contraction and ventilator assistance, and the asynchrony index (AI).


Options:
A: Arm Label: NAVA-PS; Type: EXPERIMENTAL; Interventions: Device: noninvasive respiratory support with NAVA mode and PSV | Arm Label: PS-NAVA; Type: EXPERIMENTAL; Interventions: Device: noninvasive respiratory support with NAVA mode and PSV | Intervention Type: DEVICE; Name: noninvasive respiratory support with NAVA mode and PSV; Assigned to Arm(s): NAVA-PS, PS-NAVA
B: Arm Label: NCPAP; Type: ACTIVE_COMPARATOR; Interventions: Device: nasal intermittent positive pressure ventilation | Arm Label: NIPPV; Type: EXPERIMENTAL; Interventions: Device: nasal intermittent positive pressure ventilation | Intervention Type: DEVICE; Name: nasal intermittent positive pressure ventilation; Assigned to Arm(s): NCPAP, NIPPV
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Device: NIPPV | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Device: nCPAP | Intervention Type: DEVICE; Name: nCPAP; Assigned to Arm(s): B | Intervention Type: DEVICE; Name: NIPPV; Assigned to Arm(s): A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Biphasic Infant flow NCPAP | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CPAP | Intervention Type: PROCEDURE; Name: Biphasic Infant flow NCPAP; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: CPAP; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Rivaroxaban With Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects With Heart Failure and Significant Coronary Artery Disease Following an Episode of Decompensated Heart Failure
Brief Summary: The purpose of this study is to assess the effectiveness and safety of rivaroxaban compared with placebo (inactive medication), in reducing the risk of death, myocardial infarction or stroke in participants with heart failure and significant coronary artery disease following an episode of decompensated heart failure.


Options:
A: Arm Label: Clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Arm Label: Ticagrelor; Type: EXPERIMENTAL; Interventions: Drug: Ticagrelor | Intervention Type: DRUG; Name: Ticagrelor; Assigned to Arm(s): Ticagrelor | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Clopidogrel
B: Arm Label: Dabigatran dose 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 2 | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin | Arm Label: Dabigatran dose 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 1 | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Dabigatran dose 1; Assigned to Arm(s): Dabigatran dose 1 | Intervention Type: DRUG; Name: Dabigatran dose 2; Assigned to Arm(s): Dabigatran dose 2
C: Arm Label: Stratum 1/ASA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Acetylsalicylic acid, Drug: Clopidogrel | Arm Label: Stratum 1/Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban, Drug: Clopidogrel | Arm Label: Stratum 2/ASA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Acetylsalicylic acid, Drug: Ticagrelor | Arm Label: Stratum 2/Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban, Drug: Ticagrelor | Intervention Type: DRUG; Name: Acetylsalicylic acid; Assigned to Arm(s): Stratum 1/ASA, Stratum 2/ASA | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Stratum 1/Rivaroxaban, Stratum 2/Rivaroxaban | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Stratum 1/ASA, Stratum 1/Rivaroxaban | Intervention Type: DRUG; Name: Ticagrelor; Assigned to Arm(s): Stratum 2/ASA, Stratum 2/Rivaroxaban
D: Arm Label: Rivaroxaban 2.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban, Other: Standard of care for heart failure and coronary artery disease | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Other: Standard of care for heart failure and coronary artery disease | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Rivaroxaban 2.5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: OTHER; Name: Standard of care for heart failure and coronary artery disease; Assigned to Arm(s): Placebo, Rivaroxaban 2.5 mg

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Rivaroxaban With Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects With Heart Failure and Significant Coronary Artery Disease Following an Episode of Decompensated Heart Failure
Brief Summary: The purpose of this study is to assess the effectiveness and safety of rivaroxaban compared with placebo (inactive medication), in reducing the risk of death, myocardial infarction or stroke in participants with heart failure and significant coronary artery disease following an episode of decompensated heart failure.


Options:
A: Arm Label: Rivaroxaban 2.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban, Other: Standard of care for heart failure and coronary artery disease | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Other: Standard of care for heart failure and coronary artery disease | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Rivaroxaban 2.5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: OTHER; Name: Standard of care for heart failure and coronary artery disease; Assigned to Arm(s): Placebo, Rivaroxaban 2.5 mg
B: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939), Drug: Enoxaparin placebo | Arm Label: Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin, Drug: Rivaroxaban placebo | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Enoxaparin | Intervention Type: DRUG; Name: Rivaroxaban placebo; Assigned to Arm(s): Enoxaparin | Intervention Type: DRUG; Name: Enoxaparin placebo; Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939)
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin titrated to an INR of 2.5-3.0 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel 75 | Intervention Type: DRUG; Name: Warfarin titrated to an INR of 2.5-3.0; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Clopidogrel 75; Assigned to Arm(s): 3
D: Arm Label: aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: aspirin | Arm Label: warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: aspirin; Assigned to Arm(s): aspirin | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): warfarin

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder
Brief Summary: The purpose of this study is to evaluate the efficacy, safety, and tolerability of vilazodone relative to placebo in adolescent outpatients (12-17) with major depressive disorder.


Options:
A: Intervention Type: DRUG; Name: DVS-SR 50 mg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: DVS-SR 100 mg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
B: Arm Label: Experimental Arm 1 - high dose; Type: EXPERIMENTAL; Interventions: Drug: Desvenlafaxine Succinate Sustained-Release | Arm Label: Experimental Arm 2 - low dose; Type: EXPERIMENTAL; Interventions: Drug: Desvenlafaxine Succinate Sustained-Release | Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Desvenlafaxine Succinate Sustained-Release; Assigned to Arm(s): Experimental Arm 1 - high dose | Intervention Type: DRUG; Name: Desvenlafaxine Succinate Sustained-Release; Assigned to Arm(s): Experimental Arm 2 - low dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Arm
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: fluoxetine (Prozac) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo plus Treatment As Usual | Intervention Type: DRUG; Name: fluoxetine (Prozac); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo plus Treatment As Usual; Assigned to Arm(s): 2
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Vilazodone 15 mg; Type: EXPERIMENTAL; Interventions: Drug: Vilazodone | Arm Label: vilazodone 30 mg; Type: EXPERIMENTAL; Interventions: Drug: Vilazodone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Vilazodone; Assigned to Arm(s): Vilazodone 15 mg | Intervention Type: DRUG; Name: Vilazodone; Assigned to Arm(s): vilazodone 30 mg

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Trial of the Impact of Mobile Phone Delivered Reminders and Travel Subsidies to Improve Childhood Immunization Coverage Rates and Timeliness in Western Kenya
Brief Summary: The project goal is to conduct a randomized controlled trial (RCT) to test whether mobile phone short message system (SMS) reminders, either with or without mobile-phone based travel subsidies will improve timeliness, coverage, and drop-out rates of routine EPI vaccines in rural western Kenya.


Options:
A: Arm Label: SMS reminder; Type: EXPERIMENTAL; Interventions: Other: SMS reminder | Arm Label: SMS reminder and Travel subsidy; Type: EXPERIMENTAL; Interventions: Other: SMS reminder, Other: Travel subsidy | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: SMS reminder and Travel subsidy 2; Type: EXPERIMENTAL; Interventions: Other: SMS reminder, Other: Travel subsidy 2 | Intervention Type: OTHER; Name: SMS reminder; Assigned to Arm(s): SMS reminder, SMS reminder and Travel subsidy, SMS reminder and Travel subsidy 2 | Intervention Type: OTHER; Name: Travel subsidy; Assigned to Arm(s): SMS reminder and Travel subsidy | Intervention Type: OTHER; Name: Travel subsidy 2; Assigned to Arm(s): SMS reminder and Travel subsidy 2
B: Arm Label: Neonatal Kit; Type: EXPERIMENTAL; Interventions: Device: Neonatal Kit | Arm Label: Neonatal Stimulation; Type: EXPERIMENTAL; Interventions: Behavioral: Neonatal Stimulation | Arm Label: Neonatal Kit and Neonatal Stimulation; Type: EXPERIMENTAL; Interventions: Device: Neonatal Kit, Behavioral: Neonatal Stimulation | Arm Label: Control (Standard Care); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Neonatal Kit; Assigned to Arm(s): Neonatal Kit, Neonatal Kit and Neonatal Stimulation | Intervention Type: BEHAVIORAL; Name: Neonatal Stimulation; Assigned to Arm(s): Neonatal Kit and Neonatal Stimulation, Neonatal Stimulation
C: Arm Label: Control arm; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: INTER-ACT arm; Type: EXPERIMENTAL; Interventions: Behavioral: INTER-ACT | Intervention Type: BEHAVIORAL; Name: INTER-ACT; Assigned to Arm(s): INTER-ACT arm
D: Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Reminders only; Type: EXPERIMENTAL; Interventions: Behavioral: Reminders | Arm Label: Reminders + Conditional financial transfer; Type: EXPERIMENTAL; Interventions: Behavioral: Reminders, Behavioral: Conditional financial transfers | Intervention Type: BEHAVIORAL; Name: Reminders; Assigned to Arm(s): Reminders + Conditional financial transfer, Reminders only | Intervention Type: BEHAVIORAL; Name: Conditional financial transfers; Assigned to Arm(s): Reminders + Conditional financial transfer

Answer: A